[Concepts, effectiveness, and perspectives of pandemic and seasonal influenza vaccines].
Identifieur interne : 000195 ( Main/Exploration ); précédent : 000194; suivant : 000196[Concepts, effectiveness, and perspectives of pandemic and seasonal influenza vaccines].
Auteurs : S. Grund [Allemagne] ; O. Wichmann ; T. Mertens ; H. HengelSource :
- Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz [ 1437-1588 ] ; 2013.
Descripteurs français
- KwdFr :
- MESH :
- tendances : Vaccination de masse.
- usage thérapeutique : Vaccins antigrippaux.
- épidémiologie : Allemagne, Grippe humaine.
- Conception de médicament, Grippe humaine, Humains, Pandémies, Prévalence, Résultat thérapeutique, Saisons, Vaccination de masse, Vaccins antigrippaux.
English descriptors
- KwdEn :
- Drug Design, Germany (epidemiology), Humans, Influenza Vaccines (classification), Influenza Vaccines (therapeutic use), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Mass Vaccination (statistics & numerical data), Mass Vaccination (trends), Pandemics (prevention & control), Pandemics (statistics & numerical data), Prevalence, Seasons, Treatment Outcome.
- MESH :
- chemical , classification : Influenza Vaccines.
- epidemiology : Germany, Influenza, Human.
- prevention & control : Influenza, Human, Pandemics.
- statistics & numerical data : Mass Vaccination, Pandemics.
- chemical , therapeutic use : Influenza Vaccines.
- trends : Mass Vaccination.
- Drug Design, Humans, Prevalence, Seasons, Treatment Outcome.
Abstract
For the first time in history, the conditions to influence the course of an influenza pandemic through vaccination were set during the influenza A H1N1 pandemic in 2009. The specific requirements for pandemic vaccines are to be highly immunogenic in immunologically naive individuals and to be producible quickly in large quantities. In contrast, seasonal influenza vaccines induce a booster response and a broadening of preexisting immunity. In this article the concepts of seasonal and pandemic influenza vaccines and data on their immunogenicity and clinical efficacy are reviewed and discussed. In the upcoming years, seasonal influenza vaccination will continue to be based on inactivated split-virion and subunit vaccines or the live attenuated cold-adapted vaccine. The pandemic vaccines used in 2009 proved to be more immunogenic than expected from prepandemic vaccine trials, while the adverse events observed with AS03-adjuvanted vaccines call their future use into question. However, neither seasonal nor pandemic influenza vaccines can be regarded to be an ideal solution, because they have to be frequently adapted to new virus strains and they lack effectiveness in particular risk groups. They can be regarded as interim approaches to highly immunogenic vaccines that hopefully become available in the future. The underlying principles of future vaccines are also presented in this article.
DOI: 10.1007/s00103-012-1590-4
PubMed: 23275959
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Concepts, effectiveness, and perspectives of pandemic and seasonal influenza vaccines].</title><author><name sortKey="Grund, S" sort="Grund, S" uniqKey="Grund S" first="S" last="Grund">S. Grund</name><affiliation wicri:level="3"><nlm:affiliation>Institut für Virologie, Heinrich-Heine-Universität Düsseldorf, Universitätsstr. 1, Geb. 22.21, 40225, Düsseldorf, Deutschland. Sebastian.Grund@med.uni-duesseldorf.de</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institut für Virologie, Heinrich-Heine-Universität Düsseldorf, Universitätsstr. 1, Geb. 22.21, 40225, Düsseldorf</wicri:regionArea><placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region><region type="district" nuts="2">District de Düsseldorf</region><settlement type="city">Düsseldorf</settlement></placeName></affiliation></author><author><name sortKey="Wichmann, O" sort="Wichmann, O" uniqKey="Wichmann O" first="O" last="Wichmann">O. Wichmann</name></author><author><name sortKey="Mertens, T" sort="Mertens, T" uniqKey="Mertens T" first="T" last="Mertens">T. Mertens</name></author><author><name sortKey="Hengel, H" sort="Hengel, H" uniqKey="Hengel H" first="H" last="Hengel">H. Hengel</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23275959</idno><idno type="pmid">23275959</idno><idno type="doi">10.1007/s00103-012-1590-4</idno><idno type="wicri:Area/Main/Corpus">000208</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000208</idno><idno type="wicri:Area/Main/Curation">000208</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000208</idno><idno type="wicri:Area/Main/Exploration">000208</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Concepts, effectiveness, and perspectives of pandemic and seasonal influenza vaccines].</title><author><name sortKey="Grund, S" sort="Grund, S" uniqKey="Grund S" first="S" last="Grund">S. Grund</name><affiliation wicri:level="3"><nlm:affiliation>Institut für Virologie, Heinrich-Heine-Universität Düsseldorf, Universitätsstr. 1, Geb. 22.21, 40225, Düsseldorf, Deutschland. Sebastian.Grund@med.uni-duesseldorf.de</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institut für Virologie, Heinrich-Heine-Universität Düsseldorf, Universitätsstr. 1, Geb. 22.21, 40225, Düsseldorf</wicri:regionArea><placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region><region type="district" nuts="2">District de Düsseldorf</region><settlement type="city">Düsseldorf</settlement></placeName></affiliation></author><author><name sortKey="Wichmann, O" sort="Wichmann, O" uniqKey="Wichmann O" first="O" last="Wichmann">O. Wichmann</name></author><author><name sortKey="Mertens, T" sort="Mertens, T" uniqKey="Mertens T" first="T" last="Mertens">T. Mertens</name></author><author><name sortKey="Hengel, H" sort="Hengel, H" uniqKey="Hengel H" first="H" last="Hengel">H. Hengel</name></author></analytic><series><title level="j">Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz</title><idno type="eISSN">1437-1588</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Drug Design</term><term>Germany (epidemiology)</term><term>Humans</term><term>Influenza Vaccines (classification)</term><term>Influenza Vaccines (therapeutic use)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Mass Vaccination (statistics & numerical data)</term><term>Mass Vaccination (trends)</term><term>Pandemics (prevention & control)</term><term>Pandemics (statistics & numerical data)</term><term>Prevalence</term><term>Seasons</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Allemagne (épidémiologie)</term><term>Conception de médicament</term><term>Grippe humaine ()</term><term>Grippe humaine (épidémiologie)</term><term>Humains</term><term>Pandémies ()</term><term>Prévalence</term><term>Résultat thérapeutique</term><term>Saisons</term><term>Vaccination de masse ()</term><term>Vaccination de masse (tendances)</term><term>Vaccins antigrippaux ()</term><term>Vaccins antigrippaux (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="classification" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Germany</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term><term>Pandemics</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Mass Vaccination</term><term>Pandemics</term></keywords><keywords scheme="MESH" qualifier="tendances" xml:lang="fr"><term>Vaccination de masse</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Mass Vaccination</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Allemagne</term><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Design</term><term>Humans</term><term>Prevalence</term><term>Seasons</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Conception de médicament</term><term>Grippe humaine</term><term>Humains</term><term>Pandémies</term><term>Prévalence</term><term>Résultat thérapeutique</term><term>Saisons</term><term>Vaccination de masse</term><term>Vaccins antigrippaux</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">For the first time in history, the conditions to influence the course of an influenza pandemic through vaccination were set during the influenza A H1N1 pandemic in 2009. The specific requirements for pandemic vaccines are to be highly immunogenic in immunologically naive individuals and to be producible quickly in large quantities. In contrast, seasonal influenza vaccines induce a booster response and a broadening of preexisting immunity. In this article the concepts of seasonal and pandemic influenza vaccines and data on their immunogenicity and clinical efficacy are reviewed and discussed. In the upcoming years, seasonal influenza vaccination will continue to be based on inactivated split-virion and subunit vaccines or the live attenuated cold-adapted vaccine. The pandemic vaccines used in 2009 proved to be more immunogenic than expected from prepandemic vaccine trials, while the adverse events observed with AS03-adjuvanted vaccines call their future use into question. However, neither seasonal nor pandemic influenza vaccines can be regarded to be an ideal solution, because they have to be frequently adapted to new virus strains and they lack effectiveness in particular risk groups. They can be regarded as interim approaches to highly immunogenic vaccines that hopefully become available in the future. The underlying principles of future vaccines are also presented in this article.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23275959</PMID><DateCompleted><Year>2013</Year><Month>11</Month><Day>25</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1437-1588</ISSN><JournalIssue CitedMedium="Internet"><Volume>56</Volume><Issue>1</Issue><PubDate><Year>2013</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz</Title><ISOAbbreviation>Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz</ISOAbbreviation></Journal><ArticleTitle>[Concepts, effectiveness, and perspectives of pandemic and seasonal influenza vaccines].</ArticleTitle><Pagination><MedlinePgn>76-86</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00103-012-1590-4</ELocationID><Abstract><AbstractText>For the first time in history, the conditions to influence the course of an influenza pandemic through vaccination were set during the influenza A H1N1 pandemic in 2009. The specific requirements for pandemic vaccines are to be highly immunogenic in immunologically naive individuals and to be producible quickly in large quantities. In contrast, seasonal influenza vaccines induce a booster response and a broadening of preexisting immunity. In this article the concepts of seasonal and pandemic influenza vaccines and data on their immunogenicity and clinical efficacy are reviewed and discussed. In the upcoming years, seasonal influenza vaccination will continue to be based on inactivated split-virion and subunit vaccines or the live attenuated cold-adapted vaccine. The pandemic vaccines used in 2009 proved to be more immunogenic than expected from prepandemic vaccine trials, while the adverse events observed with AS03-adjuvanted vaccines call their future use into question. However, neither seasonal nor pandemic influenza vaccines can be regarded to be an ideal solution, because they have to be frequently adapted to new virus strains and they lack effectiveness in particular risk groups. They can be regarded as interim approaches to highly immunogenic vaccines that hopefully become available in the future. The underlying principles of future vaccines are also presented in this article.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Grund</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institut für Virologie, Heinrich-Heine-Universität Düsseldorf, Universitätsstr. 1, Geb. 22.21, 40225, Düsseldorf, Deutschland. Sebastian.Grund@med.uni-duesseldorf.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wichmann</LastName><ForeName>O</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Mertens</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Hengel</LastName><ForeName>H</ForeName><Initials>H</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Konzepte, Wirksamkeit und Perspektiven pandemischer und nichtpandemischer Influenzaimpfungen.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz</MedlineTA><NlmUniqueID>101181368</NlmUniqueID><ISSNLinking>1436-9990</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015195" MajorTopicYN="N">Drug Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D032541" MajorTopicYN="N">Mass Vaccination</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="Y">Seasons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23275959</ArticleId><ArticleId IdType="doi">10.1007/s00103-012-1590-4</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li></country><region><li>District de Düsseldorf</li><li>Rhénanie-du-Nord-Westphalie</li></region><settlement><li>Düsseldorf</li></settlement></list><tree><noCountry><name sortKey="Hengel, H" sort="Hengel, H" uniqKey="Hengel H" first="H" last="Hengel">H. Hengel</name><name sortKey="Mertens, T" sort="Mertens, T" uniqKey="Mertens T" first="T" last="Mertens">T. Mertens</name><name sortKey="Wichmann, O" sort="Wichmann, O" uniqKey="Wichmann O" first="O" last="Wichmann">O. Wichmann</name></noCountry><country name="Allemagne"><region name="Rhénanie-du-Nord-Westphalie"><name sortKey="Grund, S" sort="Grund, S" uniqKey="Grund S" first="S" last="Grund">S. Grund</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeAllemagneV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000195 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000195 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= GrippeAllemagneV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:23275959
|texte= [Concepts, effectiveness, and perspectives of pandemic and seasonal influenza vaccines].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:23275959" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeAllemagneV3
| This area was generated with Dilib version V0.6.35. |  |